Core Viewpoint - Shuttle Pharmaceuticals is making significant progress in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma, with 63% enrollment achieved and 72% of enrolled patients completing all treatment cycles, indicating a well-tolerated therapy [1][6]. Recent Activities - The Phase 2 clinical trial is being conducted in collaboration with leading cancer centers across the U.S. and aims to complete enrollment later this year, with data readouts expected in 2026 [1][3]. - Ropidoxuridine is designed as a radiation sensitizer to improve treatment outcomes for glioblastoma patients, a type of brain cancer with no known cure [1][7]. Clinical Trial Design - The trial involves randomizing 40 patients into two dose levels: 20 patients receiving 1,200 mg/day and 20 patients receiving 960 mg/day, to identify the optimal dose for glioblastoma treatment in combination with radiation therapy [2]. Market Opportunity - Approximately 800,000 patients in the U.S. receive radiation therapy for cancer annually, with 50% treated for curative purposes. The market for radiation sensitizers targets the 400,000 patients treated curatively, expected to grow by over 22% in the next five years [4]. Financial Update - The company ended the quarter with $4.8 million in cash after a private placement that raised $4.25 million in June 2025 [6]. - A reverse stock split was completed in June 2025 as part of a strategic initiative for Nasdaq compliance [6]. Leadership Changes - George Scorsis was appointed as the Chairman of the Board, and Christopher Cooper, the current Interim CEO, was appointed to the Board, both bringing extensive experience in management and finance [6].

Core Insights - Shuttle Pharmaceuticals is advancing its Phase 2 clinical trial for Ropidoxuridine, targeting glioblastoma patients, with nearly 50% enrollment achieved and positive early results regarding drug tolerance [1][2][3] - The company aims to finalize enrollment by the end of 2025, with data readout expected in 2026 [1][3] Company Overview - Shuttle Pharmaceuticals is a specialty pharmaceutical company founded in 2012, focused on enhancing outcomes for cancer patients undergoing radiation therapy [8] - The company's mission is to develop therapies that maximize the effectiveness of radiation therapy while minimizing side effects [8] Clinical Trial Details - The Phase 2 trial involves randomizing 40 patients into two dosage groups (1,200 mg/day and 960 mg/day) to identify the optimal dose for glioblastoma treatment [3] - Following the identification of the optimal dose, an additional 14 patients will be enrolled to achieve statistical significance in survival outcomes compared to historical controls [3] Market Opportunity - Approximately 800,000 patients in the US receive radiation therapy annually, with 50% treated for curative purposes, representing a significant market for radiation sensitizers [6] - The market for radiation sensitizers is expected to grow by over 22% in the next five years, driven by the 400,000 patients treated for curative purposes [6] Industry Impact - The trial is seen as critical for the radiation therapy industry, aiming to leverage radiation sensitizers to improve cancer cure rates and patient quality of life [5]